Clinical Trials Logo

Decompensated Liver Cirrhosis clinical trials

View clinical trials related to Decompensated Liver Cirrhosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05871463 Recruiting - Clinical trials for Decompensated Liver Cirrhosis

Effect of Mesenchymal Stem Cells-derived Exosomes in Decompensated Liver Cirrhosis

Start date: May 26, 2023
Phase: Phase 2
Study type: Interventional

Decompensated liver cirrhosis (LC), a life-threatening complication of chronic liver disease, is one of the major indications for liver transplantation. Recently, mesenchymal stem cell (MSC) transfusion has been shown to lead to the regression of liver fibrosis in mice and humans. However, little is known about MSC-exosome therapy. We will evaluate the therapeutic potential of mesenchymal stem Cell-Exosomes as an alternative to cell therapy in Cirrhotic patients. This study examined the safety and efficacy of umbilical cord-derived MSC-exosomes in patients with decompensated LC.

NCT ID: NCT04801290 Recruiting - Clinical trials for Decompensated Liver Cirrhosis

TIPS in Patients With Decompensated Liver Cirrhosis

Start date: August 29, 2019
Phase:
Study type: Observational [Patient Registry]

This is a single center patient registry of patients receiving a transjugular intrahepatic portosystemic shunt (TIPS) at Hannover Medical School. By collecting and analyzing clinical data as well as blood samples, the overall aim is to optimize TIPS therapy (e.g. specify selection criteria).

NCT ID: NCT03945487 Recruiting - Clinical trials for Decompensated Liver Cirrhosis

Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis

Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

Decompensated liver cirrhosis is a life-threatening chronic liver disease with high mortality. Liver transplantation is the only option that can improve the survival of these patients; however, this procedure is associated with several limitations, such as the severe shortage of donor livers, long waiting lists, multiple complications, and high cost. Our and other previous studies have demonstrated that marrow bone-derived mesenchymal stem cells (BM-MSC) or unbilical cord derived MSC (UC-MSC) infusion is clinically safe and could improve liver function in patients with decompensated liver cirrhosis. However, the long-term outcomes of MSC infusion have not been reported until now. This prospective and randomized controlled study examined the longer-term safety and efficacy of UC-MSC in patients with decompensated liver cirrhosis.